Morgan Wallen, Jason Aldean to Play Benefit for Covenant School
A benefit show headlined by Jason Aldean and Morgan Wallen, titled A Covenant Knight at the Opry House, hopes to offer a shoulder in the the midst of sorrow.
Source: 975kgkl.com
📰 Chas Schultz News
Page 5 - Chas Schultz News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Chas Schultz. Real-time updates on events, politics, business and more.
New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023
Early-Stage Candidates for Primary Hyperparathyroidism and Thyroid Eye Disease Also Featured Crinetics Founder & CEO, Scott Struthers Accepted John D. Baxter Prize for Entrepreneurship from... | June 21, 2023
Source: marketscreener.com
Crinetics to Highlight Broad Pipeline at ENDO 2023
Endocrine Society President to Present Crinetics CEO with John D. Baxter Prize for EntrepreneurshipSAN DIEGO, June 09, 2023 -- Crinetics Pharmaceuticals, Inc. today announced upcoming... | June 9, 2023
Source: marketscreener.com
Crinetics Pharmaceuticals Announces Inducement Grants Under
SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the...
Aline Sherwood Chas Schultz Corey Davis Corporate Communications Lifesci Advisors Crinetics Pharmaceuticals Inc
Source: globenewswire.com
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 10, 2023 -- Crinetics Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare... | April 10, 2023
Corey Davis Aline Sherwood Chas Schultz Crinetics Pharmaceuticals Lifesci Advisors Globenewswire Inc
Source: marketscreener.com
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Paltusotine’s Phase 3 PATHFNDR-1 study enrollment complete and topline data expected in 3Q 2023Paltusotine’s Phase 3 PATHFNDR-2 study enrollment ongoing with topline data now expected in... | February 28, 2023
Source: marketscreener.com
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10.02.2023 - SAN DIEGO, Feb. 10, 2023 (GLOBE NEWSWIRE) - Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and ...
Chas Schultz Corey Davis Aline Sherwood Lifesci Advisors Corporate Communications Scienta Communications
Source: wallstreet-online.de
Crinetics Pharmaceuticals Announces Inducement Grants Under
SAN DIEGO, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the...
Chas Schultz Corey Davis Aline Sherwood Lifesci Advisors Corporate Communications Scienta Communications
Source: globenewswire.com
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
SAN DIEGO, Oct. 13, 2022 -- Crinetics Pharmaceuticals, Inc. today announced the completion of enrollment in the Phase 3 PATHFNDR-1 study. PATHFNDR-1 is one of two ongoing, placebo-controlled Phase... | October 13, 2022
Source: marketscreener.com
Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as
SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the appointment of Dana Pizzuti, M.D., as...
Source: globenewswire.com